[Reporting of conflict of interest in cost-effectiveness analyses of healthcare interventions].
作者信息
Catalá-López Ferrán, Ridao Manuel
机构信息
Departamento de Medicina, Universidad de Valencia/CIBERSAM e Instituto de Investigación Sanitaria INCLIVA, Valencia, España; Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada; Fundación Instituto de Investigación en Servicios de Salud, Valencia, España.
Instituto Aragonés de Ciencias de la Salud (I+CS), Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Zaragoza, España; FISABIO-Salud Pública, Valencia, España.
出版信息
Aten Primaria. 2017 Feb;49(2):118-120. doi: 10.1016/j.aprim.2016.03.010. Epub 2016 Jul 14.
Abstract
摘要
相似文献
1
[Reporting of conflict of interest in cost-effectiveness analyses of healthcare interventions].[医疗保健干预措施成本效益分析中的利益冲突报告]
Aten Primaria. 2017 Feb;49(2):118-120. doi: 10.1016/j.aprim.2016.03.010. Epub 2016 Jul 14.
2
[Improving the transparency and credibility of cost-effectiveness analysis of healthcare interventions].提高医疗保健干预措施成本效益分析的透明度和可信度
Rev Esp Salud Publica. 2016 Mar 23;90:E1.
3
Where is the care in managed care?
Shma. 1996 Dec 27;27(524):1-4.
4
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.西班牙成本效益分析报告方法与结果的质量：一项方法学系统评价
Syst Rev. 2016 Jan 7;5:6. doi: 10.1186/s13643-015-0181-5.
5
Relationship of Industry Sponsorship to Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
JAMA Oncol. 2016 Apr;2(4):548-9. doi: 10.1001/jamaoncol.2016.0139.
6
Relationship of Industry Sponsorship to Results of Cost-Effectiveness Analyses of Drugs Used in Breast Cancer Treatment--Reply.
JAMA Oncol. 2016 Apr;2(4):549. doi: 10.1001/jamaoncol.2016.0142.
7
Medical technology "arms race" adds billions to the nation's bills: the price of health.医疗技术“军备竞赛”使国家账单增加数十亿美元：健康的代价。
N Y Times Web. 1991 Apr 29:A1, B8.
8
Two birds, one stone: cover the uninsured by fixing Medicare.一石二鸟：通过完善医疗保险覆盖未参保者。
Minn Med. 2009 Mar;92(3):40-1.
9
Understanding cost-effectiveness.理解成本效益。
Clin Microbiol Infect. 2010 Dec;16(12):1707-12. doi: 10.1111/j.1469-0691.2010.03331.x.
10
Hard choices: patient autonomy in an era of health care cost containment.
Jurimetrics. 1990 Summer;30(4):483-500.
引用本文的文献
1
[Potential sponsorship bias in cost-effectiveness analyses of healthcare interventions: A cross-sectional analysis].[医疗保健干预措施成本效益分析中的潜在赞助偏差：一项横断面分析]
Aten Primaria. 2017 Jun-Jul;49(6):335-342. doi: 10.1016/j.aprim.2016.08.001. Epub 2017 Jan 3.
本文引用的文献
1
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.西班牙成本效益分析报告方法与结果的质量：一项方法学系统评价
Syst Rev. 2016 Jan 7;5:6. doi: 10.1186/s13643-015-0181-5.
2
When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.何时他汀类药物在心血管预防方面具有成本效益？他汀类药物经济学评价中的赞助偏见和结论的系统评价。
PLoS One. 2013 Jul 8;8(7):e69462. doi: 10.1371/journal.pone.0069462. Print 2013.
3
Declaring competing interests. Types of competing interests would be of interest.声明利益冲突。利益冲突的类型将是人们感兴趣的。
BMJ. 2001 Nov 17;323(7322):1187-8.
4
Declaring financial competing interests: survey of five general medical journals.声明财务利益冲突：对五家综合医学期刊的调查
BMJ. 2001 Aug 4;323(7307):263-4. doi: 10.1136/bmj.323.7307.263.
5
[Cost effectiveness analysis in health].[卫生领域的成本效益分析]
Aten Primaria. 2001 Mar 15;27(4):275-8. doi: 10.1016/s0212-6567(01)78808-7.
6
Conflict of interest and cost-effectiveness analysis.利益冲突与成本效益分析。
JAMA. 1999 Oct 20;282(15):1474-5. doi: 10.1001/jama.282.15.1474.
Zotero 插件